

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior listings.:

1. (Currently Amended) A method of enhancing an immune response to an antigen in a mammal comprising:

~~(a) culturing naïve T cells with anti-CD3- and anti-CD28-coated beads to produce a lymphocyte conditioned media adjuvant;~~

~~——(b) culturing monocytes with said lymphocyte-conditioned media adjuvant in the absence of cytokines, such as GM-CSF, to produce immature dendritic cells;~~

~~——(c) culturing said immature dendritic cells from step (b) with said lymphocyte conditioned media adjuvant in the presence of cytokines, such as GM-CSF, to produce mature dendritic cells; and~~

~~——(d) administering said an antigen in combination with lymphocyte conditioned medium-adjuvant enriched with said mature dendritic cells- derived from peripheral blood mononuclear cells activated with anti-CD3- and anti-CD28-coated beads in a culture medium-in-combination-with-a-vaccine-of-said-antigen to said mammal.~~

2. (Canceled)

3. (Withdrawn) The method of Claim 1, wherein said antigen is HIV-1 or HIV-2.

4. (Withdrawn) The method of Claim 1, wherein said antigen is hepatitis-B.

5. (Withdrawn) The method of Claim 1, wherein said antigen is tetanus toxoid.

6. (Original) The method of Claim 1, wherein said antigen is prostate-specific antigen.

7. (Withdrawn) The method of Claim 1, wherein said antigen is hepatitis-A.

8. (Withdrawn) The method of Claim 1, wherein said antigen is diptheria.
9. (Original) The method of Claim 1, wherein the dosage of said lymphocyte conditioned medium is about 10 μ g to about 500 μ g.
10. (Original) The method of Claim 1, wherein said administration is selected from the group consisting of intracutaneous, subcutaneous and intramuscular injection and combinations thereof.
11. (Original) The method of Claim 1, wherein said administration is selected from the group consisting of weekly, biweekly, monthly, and yearly and combinations thereof.
12. (Withdrawn) A vaccine adjuvant composition for stimulation of an immune response in a host animal comprising supernatant derived from activated human lymphocytes cells cultured with growth media.
13. (Withdrawn) The composition of Claim 12, wherein said activation of said cells is effected with antibodies to CD3/CD28.
14. (Withdrawn) A vaccine adjuvant composition for stimulation of an immune response in a host animal comprising processed activated human lymphocytes cells cultured with growth media.
15. (Withdrawn) The composition of Claim 14, wherein said activation of said cells is effected with antibodies to CD3/CD28.
16. (New) A method of enhancing an immune response to an antigen in a mammal, comprising administering to the mammal a vaccine comprising an antigen and culture medium supernatant derived from peripheral blood mononuclear cells activated with anti-CD3- and anti-CD28-coated beads in the culture medium.